| NCT06634420 | HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) | ACTIVE_NOT_RECRUITING | PHASE3 | 2025-01-15 | 2027-09 | 2026-04 |
| NCT06672237 | A Phase 3 Study of NTLA-2001 in ATTRv-PN | RECRUITING | PHASE3 | 2024-11-22 | 2028-08 | 2027-07 |
| NCT06622668 | NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease | WITHDRAWN | PHASE1, PHASE2 | 2024-11-20 | 2025-01-09 | 2025-01-09 |
| NCT06128629 | MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | RECRUITING | PHASE3 | 2023-12-13 | 2028-04 | 2027-12 |
| NCT05066165 | Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | TERMINATED | PHASE1, PHASE2 | 2021-12-17 | 2022-08-31 | 2022-07-21 |
| NCT05120830 | NTLA-2002 in Adults With Hereditary Angioedema (HAE) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-12-10 | 2026-03-31 | 2024-04-04 |
| NCT04601051 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM) | ACTIVE_NOT_RECRUITING | PHASE1 | 2020-11-05 | 2026-08 | 2025-08 |